Brought to you by 
Watson gets US and Canadian rights to Antares' Anturol
19 Aug 2011
Executive Summary
Watson Pharmaceuticals Inc. (urology and women’s health products) has licensed exclusive US and Canadian rights to Antares Pharma Inc.’s (self-injection and gel therapeutics) Anturol topical oxybutynin gel for overactive bladder (OAB). The FDA is reviewing the NDA and set a December 8, 2011 PDUFA date.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Watson gets US and Canadian rights to Antares' Anturol
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice